文献速递肺外科

血清生物标志物或可预测4厘米以下淋巴结阴性非小细胞肺癌复发

Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters.
PubMed 文献 · Ann Thorac Surg · 2017-09-28

本研究利用机构生物样本库中123例已切除、淋巴结阴性、小于4厘米的非小细胞肺癌患者,盲法检测术前血清47种生物标志物。随机森林分析构建七种标志物组合,交叉验证特异性91%、敏感性22%、阴性预测值83%、阳性预测值36%、准确率78%,AUC为0.70,提示血清标志物可能有助于复发风险分层。

要点

  • 七种血清标志物组合交叉验证特异性91%、敏感性22%、准确率78%。
  • 该组合阴性预测值83%,有助于识别复发低风险患者。
  • 研究仅纳入123例患者,复发23例,需外部验证。

核心结论

  • 血清生物标志物可能有助于对小于4厘米的淋巴结阴性非小细胞肺癌切除术后患者进行复发风险分层。

研究设计与样本

  • 利用机构生物样本库中超过1800例病例,识别出123例已切除、淋巴结阴性、小于4厘米的非小细胞肺癌患者,中位随访58.2个月。
  • 术前血清标本盲法检测47种与转移进展相关的生物标志物,涵盖血管生成、能量代谢、凋亡和炎症等生物学过程。
  • 采用受试者工作特征曲线和log rank检验评估单个标志物与复发的关系,随后用随机森林分析生成并交叉验证多分析物组合。

主要发现

  • 队列中23例患者出现复发。
  • 七种标志物组合(人附睾蛋白4、胰岛素样生长因子结合蛋白1、β-人绒毛膜促性腺激素、卵泡抑素、催乳素、血管生成素-2、肝细胞生长因子)交叉验证特异性91%、敏感性22%、阴性预测值83%、阳性预测值36%、准确率78%,AUC为0.70。

临床怎么用

  • 该七种血清标志物组合或可用于辅助识别小于4厘米淋巴结阴性非小细胞肺癌术后复发低风险患者,但敏感性较低,需结合其他临床因素综合评估。

局限性

  • 研究为单机构回顾性生物样本库分析,样本量123例、复发事件23例,结果需外部前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A significant proportion of patients who undergo lung resection for less than 4 cm non-small cell lung cancer (NSCLC) will die of disease recurrence within 5 years. The ability to identify patients at greatest risk for recurrence may help individualize treatment and surveillance regimens and improve outcomes. We hypothesized that a serum-based biomarker panel could help risk stratify patients with node-negative NSCLC less than 4 cm for recurrence after lung resection. METHODS: An institutional biorepository of more than 1,800 cases was used to identify patients with resected, node-negative NSCLC less than 4 cm in size. Clinical and radiographic data were collected. Preoperative serum specimens were evaluated in a blinded manner for 47 biomarkers that sampled biological processes associated with metastatic progression, including angiogenesis, energy metabolism, apoptosis, and inflammation. Receiver-operating characteristics curves and log rank tests were used to evaluate individual biomarkers with respect to recurrence, followed by random forest analysis to generate and cross validate a multiple-analyte panel to risk stratify patients for recurrence. RESULTS: The cohort included 123 patients with a median follow-up of 58.2 months; 23 patients had recurrences. A seven-analyte panel consisting of human epididymis protein 4, insulinlike growth factor-binding protein 1, beta-human chorionic gonadotropin, follistatin, prolactin, angiopoietin-2, and hepatocyte growth factor optimally identified patients with disease recurrence with a cross-validated specificity of 91%, sensitivity of 22%, negative predictive value of 83%, positive predictive value of 36%, and accuracy of 78%, providing an area under the receiver-operating characteristics curve of 0.70. CONCLUSIONS: Serum-based biomarkers may be useful for risk stratifying patients with node-negative NSCLC less than 4 cm for recurrence after lung resection.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Seder CW, Arndt AT, Jordano L, et al. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017. PMID: 28964418. doi:10.1016/j.athoracsur.2017.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。